4584: Kidswell Bio Corporation - Summary | Jitta

Kidswell Bio Corporation

TYO:4584

Price
¥201.00
Loss Chance
54.1%
2.60JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
142 / 184
2,890 / 3,513
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (62)
Financial Strength (34)
Return to Shareholders (0)
Competitive Advantage (45)
Jitta Signs
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 609.63% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
2.60
100.00%
2.16
172.04%
4.36
368.05%
Biotechnology
3.32
100.00%
2.10
> 1,000%
2.52
100.00%
COMPANY DESCRIPTION
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.